October 26, 2014 12:39 AM ET

Biotechnology

Company Overview of DOV Pharmaceutical Inc.

Company Overview

As of July 19, 2010, DOV Pharmaceutical Inc. was acquired by Euthymics Bioscience, Inc. DOV Pharmaceutical, Inc., a biopharmaceutical company, engages in the discovery, in-licensing, and development of novel drug candidates for central nervous system disorders. Its product candidate include DOV 21,947, a triple reuptake inhibitor, which is in Phase II clinical trials for depression, as well as in preclinical studies for obesity; Bicifadine for the treatment of pain or analgesics, which is in Phase II/Phase III(2) clinical trials; DOV diltiazem for the treatment of hypertension and angina is in Phase I/III(3); and DOV 102,677, which is in Phase I(4) for alcohol abuse. The company also involve...

150 Pierce Street

Somerset, NJ 08873

United States

Founded in 1995

12 Employees

Phone:

732-907-3600

Fax:

732-907-3799

Key Executives for DOV Pharmaceutical Inc.

DOV Pharmaceutical Inc. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Boston Biomedical Research Institute, Inc. United States
PhaseRx, Inc. United States
Martek Biosciences Boulder Corporation United States
AMBA Biosciences, LLC United States
ImaginAb, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DOV Pharmaceutical Inc., please visit www.dovpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.